Appointments at Elan, Inspire Pharmaceuticals, BioVex and Lux Biosciences – People on the move
Elan has hired Eliseo Oreste Salinas as executive vice president (EVP) and chief medical officer. Salinas has 20 years of industry experience at companies including Adolor, Shire and Wyeth-Ayerst.
Huw Jones has been named CEO of Atlantic Pharmaceuticals. Most recently Jones was a director of Ardana and has also worked at CV Therapeutics, Elan and SmithKlineBeecham.
Inspire Pharmaceuticals has made a number of managerial changes. Kim Brazzell is now EVP, medical and scientific affairs; Andrew Koven is EVP and chief administrative and legal officer; and Joseph Schachle is EVP, pulmonary business.
The other new appointments are: Joseph Spagnardi, SVP, general counsel and secretary; Thomas Staab, EVP and chief financial officer; Gerald St Peter, SVP, ophthalmology business; and Francisca Yanez, VP, human resources.
Stephen Kelly has joined BioVex as chief commercial officer. Before joining BioVex Kelly was CEO of Innovive Pharmaceuticals and he has also worked at Amgen, Idec and Sanofi.
Vanda Pharmaceuticals has appointed Steven Galson to its board of directors. Galson is a former acting US surgeon general and currently SVP for the civilian health operation at Science Applications International Corporation (SAIC).
James Connolly has been named as president and CEO of the Aeras Global TB Vaccine Foundation. Before joining Aeras Connolly was EVP and general manager of Wyeth Vaccines.
Lux Biosciences has hired Dean Mitchell as president and CEO. Mitchell previously held the same positions at Alpharma and has also worked at Guilford Pharmaceuticals, Bristol-Myers Squibb and GlaxoSmithKline.
John Rossi has joined the scientific advisory board at Kylin Therapeutics. Rossi has more than 30 years of experience working with RNA interference and authored more than 275 peer-reviewed papers.
